Enhanced and long term immunogenicity of a Her-2/neu multi-epitope vaccine conjugated to the carrier CRM197 in conjunction with the adjuvant Montanide

Table 1 Binding mice sera, immunized with P467-CRM-Alum or P467-CRM-Montanide, to positive or negative Her-2/neu-overexpressing cell lines

	Percentage of detected examined cells^a
Sera of mice before, and after immunization with:	SK-BR-3	518.A2
Pre-immunization	2.35	1.75
P467-CRM-Alum (10 μg)	16	3.3
P467-CRM-Alum (25 μg)	6.9	1.8
P467-CRM-Alum (50 μg)	5.6	1.4
P467-CRM-Montanide (10 μg)	21.6	6.2
P467-CRM-Montanide (25 μg)	46.4	3.7
P467-CRM-Montanide (50 μg)	17.6	2.4

^aThe values indicate the percentage of the stained Her-2/neu overexpressing SK-BR-3 cells and 518.A2 cells as control cells (Her-2/neu negative) cells, detected by FACS analysis, as described in material and methods. The sera were diluted 1/100

ISSN: 1471-2407